Natera Reports Signatera ctDNA Clearance Data Across Four Metastatic Cancers
Natera, Inc. will present real-world data on Signatera at the SITC Annual Meeting, evaluating 424 patients receiving first-line immunotherapy across four metastatic cancers. Findings demonstrate that circulating tumor DNA clearance strongly correlates with long-term survival. Patients achieving complete molecular response reported a 36-month overall survival rate of 93.2%, versus 77.9% for others, with a hazard ratio of 0.24. This analysis reinforces the clinical utility of Signatera in metastatic melanoma, renal cell carcinoma, MSI-H colorectal cancer, and non-small cell lung cancer.
Natera, Inc. (NASDAQ: NTRA) announced that it will present new clinical data on Signatera at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 4–8 in Phoenix, Arizona.
The real-world analysis evaluated outcomes for 424 patients receiving first-line immunotherapy across four metastatic cancers: stage IV melanoma, renal cell carcinoma, microsatellite instability-high colorectal cancer (MSI-H CRC), and non-small cell lung cancer (NSCLC).
According to the reported findings, circulating tumor DNA clearance was associated with long-term survival. Patients with CMRs had a 36-month overall survival rate of 93.2%, compared with 77.9% among all other patients. The reported hazard ratio was 0.24, with a P value of 0.0003.
The findings add clinical evidence for Signatera across the four metastatic cancer types included in the analysis.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.